Street Tips: Market Review on EPIX Pharmaceuticals, Inc. -
Streetinvesting.com: Market Review on EPIX Pharmaceuticals, Inc. -
EPIX Pharma Q1 Loss Narrows; Reiterates FY08 Guidance -
EPIX Pharma Q1 Loss Narrows; Backs FY08 Outlook - Quick Facts -
EPIX Pharma Posts Q1 Loss Per Share Of $0.33 Vs Loss $0.60 Last Year -
EPIX Pharma Begins Phase 2b Program For PRX-03140 In Alzheimer's Disease - Update -
EPIX Pharma Starts Phase 2b Program For PRX-03140 In Alzheimer's Disease - Quick Facts -
EPIX Pharma Initiates Clinical Trial Of PRX-03140 In Combination With Donepezil. -
MG Strategies: Epix Pharmaceuticals Inc. Review in Progress -
BRIEF: Epix imaging device meets FDA requirements: The share jumped 26% on the news. -
EPIX Pharmaceuticals Surges In Pre-Market On News -
Epix Pharma. Broadens Collaboration With Cystic Fibrosis Foundation Therapeutics - Quick Facts -
EPIX Pharmac Expands Collaboration With Cystic Fibrosis Foundation Therapeutics -
EPIX Pharmaceuticals Closes At New Low -